HCG API: The Affordable Alternative to Recombinant

Urine-derived HCG exhibits essentially identical pharmacological efficacy to recombinant HCG; however, the development of recombinant products and production line costs are significantly higher. In contrast, urine-derived HCG employs a mature extraction process with lower raw material costs and meets regulatory requirements after appropriate processing, offering superior cost-effectiveness as an economically viable alternative to recombinant formulations.